Efectos adversos neuropsiquiátricos de drogas inmunosupresoras utilizadas en Reumatología

María Virginia Chiappe; Dario Scublinsky

doi:10.47196/rar.v24i4.47

María Virginia Chiappe Hospital de Emergencias Psiquiátricas Torcuato de Alvear, Ciudad Autónoma de Buenos Aires, Argentina
Dario Scublinsky Clínica y Maternidad Suizo Argentina, Ciudad Autónoma de Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v24i4.47

Palabras clave: efectos adversos neuropsiquiátricos, drogas inmunosupresoras, reumatología

Resumen

El uso de fármacos inmunosupresores ha ido incrementándose en las últimas décadas de la mano de un mayor conocimiento de la fisiopatología del sistema inmune y el desarrollo de la tecnología aplicada para generar drogas de alta complejidad. La utilización de dichos fármacos inmunosupresores puede producir como efecto adverso tanto manifestaciones neurológicas como psiquiátricas. El objetivo de esta revisión es describir los efectos adversos neuropsiquiátricos de las principales drogas inmunosupresoras usadas para el tratamiento de las enfermedades reumatológicas.

Biografía del autor/a

María Virginia Chiappe, Hospital de Emergencias Psiquiátricas Torcuato de Alvear, Ciudad Autónoma de Buenos Aires, Argentina

Médica Psiquiatra, Primera Cátedra de Farmacología, Facultad de Medicina, Universidad de Buenos Aires

Dario Scublinsky, Clínica y Maternidad Suizo Argentina, Ciudad Autónoma de Buenos Aires, Argentina

Médico Reumatólogo, Primera Cátedra de Farmacología, Facultad de Medicina, Universidad de Buenos Aires

Citas

I. Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta-analy-sis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of Ame-rican College of Rheumatology criteria scores 20, 50, and 70. Biologics. 2012; 6:429-64.

II. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-bloc-ker therapy. Arch Neurol. 2009; 66 (4):490.

III. Mir Subías A et al. Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infre-quent but important complication of infliximab in Crohn's disease. Gastroenterol Hepatol. 2013; 36(2):81-5.

IV. European Medicines Agency. (EMA) http://www. ema.europa.eu/ema/

V. Food Drug and Administration. (FDA) http:// www.fda.gov/

VI. Cochrane. http://www.thecochranelibrary.com

VII. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antago-nist therapy. Arthritis Rheum 2006; 54:1429-34.

VIII. Seror R, Richez C, Sordet C, Rist S, Gossec L, Di-rez G, Houvenagel E, et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French na tional survey. Rheumatology (Oxford). 2013 May; 52(5):868-74.

IX. Pfueller CF, Seipelt E, Zipp F, Paul F. Multiple sclerosis following etanercept treatment for ankylosing spondy-litis. Scand J Rheumatol. 2008 Sep-Oct; 37(5):397-9.

X. Al Saieg N, Luzar MJ. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol. 2006 Jun; 33(6):1202-4.

XI. B ensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E. Adalimumab-associated multiple sclerosis. J Rheumatol. 2007 Jan; 34(1):239-40.

XII. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing pre-vious disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68(6):805-11.

XIII. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68(6):797-804.

XIV. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly sub-cutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009 Jun; 68(6):789-796.

XV. Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, et al. Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Baye-sian Metaanalysis. The Journal of Rheumatology. 2011; 38(5):835-845.

XVI. Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P et al. Golimumab, a human anti-TNF monoclonal antibody, injected subcutaneously every 4 weeks in MTX-naïve patients with active rheumatoid arthritis: 1-year and 2-year clinical, ra-diological, and physical function findings of a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken). 2013 Jul 16. [Epub ahead of print].

XVII. Combe B, Dasgupta B, Louw I, Pal S, Wollen-haupt J, Zerbini CA, Beaulieu AD et al. Efficacy and safety of golimumab as add-on therapy to di-sease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis. 2013 Nov

XVIII. [Epub ahead of print] 18. Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheuma-toid arthritis: Systematic review and metaanalysis. Semin Arthritis Rheum. 2013 Aug;43(1):9-17.

XIX. Jónsdóttir T, Zickert A, Sundelin B, Henriksson EW, van Vollenhoven RF, Gunnarsson I. Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response. Rheumatology (Oxford). 2013 May; 52(5):847-55.

XX. Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Cli-nical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012, 31; 16(4):231.

XXI. Smolen JS, Kay J, Matteson E, Landewé R et al. Insights into the efficacy of golimumab plus metho-trexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis 2013; 0:1–18.

XXII. Jani M, Hyrich KL. Abatacept in the long-term treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2012 Mar; 8(3):231-4.

XXIII. Navarra S et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase-3 trial. Lan-cet. 2011; 377(9767):721-31.

XXIV. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A et al. Disea-se Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. J Rheumatol. 2013 Nov 1. [Epub ahead of print]

XXV. Wiacek R, Kolossa K, Jankowski T, Jeka S, Kar-mowski A, Karmowski M, Gworys B. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis. Adv Clin Exp Med. 2012 May-Jun; 21(3):337-42.

XXVI. Richards BL, Spies J, McGill N, et al. Effect of le-flunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J 2007; 37:101-7.

XXVII. Martin K, Bentaberry F, Dumoulin C, et al. Neu-ropathy associated with leflunomide: a case series. Ann Rheum Dis 2005; 64:649-50.

XXVIII. Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68(6):797-804.

XXIX. Garcia-Puig M, Fons-Estupina MC, Rives-Sola S, Berrueco-Moreno R, Cruz-Martinez O, Campistol J. Neurotoxicity due to methotrexate in paediatric patients. Description of the clinical symptoms and neu-roimaging findings Rev Neurol. Jun 16; 54(12):712-8.

XXX. Psimaras D, Bompaire F, Taillia H, Ricard D, Tai-llibert S. Central nervous system complications in patients undergoing cytotoxic chemotherapy and targeted therapies. Bull Cancer. 2012 Sep; 99(9):851-63.

XXXI. Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to stan-dard therapy: a 12-month prospective study. Lupus. 2013 Oct; 22(11):1135-41.

XXXII. Daleboudt G, Reinders M, Hartigh Jd, Huizinga T, Rabelink A, de Fijter J, Berger S. Concentra-tion-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus. 2013; 22 (2):171-9.

XXXIII. Walsh M, Solomons N, Lisk L, Jayne D. Mycophe-nolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Ma-nagement Study. Am J Kidney Dis. 2013 May; 61(5):710-5.

XXXIV. Grushkin C, Mahan JD, Mange KC, Hexham JM, Ettenger R.(2012) De novo therapy with everoli-mus and reduced-exposure cyclosporine following pediatric kidney transplantation: A prospective, multicenter, 12-month study. Pediatr Transplant. 2013 May; 17(3):237-43.

XXXV. McDiarmid SV, et al. Tacrolimus compared with cyclosporine for primary immunosuppression af-ter pediatric liver transplantation. Transplantation. 1995; 59:530–536.

XXXVI. Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver_Transplant. 2001; 7 (11) 937-942.

XXXVII. Gijtenbeek J et al. (1999) Ciclosporine: neurotoxici-ty: a review. J Neurol. 246:339–346.

XXXVIII. Walsh M, Solomons N, Lisk L, Jayne D. Mycophe-nolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Ma-nagement Study. Am J Kidney Dis. 2013 May; 61(5):710-5.

XXXIX. Kallenberg CG. Could we abandon cyclophospha-mide in systemic vasculitis and lupus nephritis? Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii62-5.

XL. Chabner B, Barnes J, Neal J et al. En: Las bases far-macológicas de la terapéutica. Goodman & Gilman. 2012: 1677-1684. Mc Graw Hill.

XLI. Bechstein WO. Neurotoxicity of calcineurin inhi-bitors: impact and clinical management. Transplant Int. 2000; 13: 313-326.

XLII. Daleboudt G, Reinders M, Hartigh Jd, Huizinga T, Rabelink A, de Fijter J, Berger S. Concentra-tion-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus. 2013; 22 (2):171-9.

XLIII. Walsh M, Solomons N, Lisk L, Jayne D. Mycophe-nolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Ma-nagement Study. Am J Kidney Dis. 2013 May; 61(5):710-5.

XLIV. Kallenberg CG. Could we abandon cyclophospha-mide in systemic vasculitis and lupus nephritis? Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii62-5.

XLV. Bösmüller C, Ollinger R, Sieb M, Weissenbacher A, Schneeberger S, Pratschke J, Margreiter R. Ta-crolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplan-tation: results of a prospective randomized trial. Ann Transplant. Dec 31; 17(4):45-51.

XLVI. Menon KV, Hakeem AR, Heaton ND. Meta-analy-sis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. Feb; 37(4):411-9.

XLVII. Kemper MJ, Spartà G, Laube GF, Miozzari M, Neuhaus TJ. Neuropsychologic side- effects of ta-crolimus in pediatric renal transplantation. Clin Transplant. 2003 Apr; 17(2):130-4.

XLVIII. Bechstein WO. Neurotoxicity of calcineurin inhi-bitors: impact and clinical management. Transplant Int. 2000; 13:313-326.

XLIX. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012 Mar; 64(3):617-29.

L. He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS et al Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Di-sord. 2013 Oct 18; 14(1):298.

LI. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012 Aug 9; 367(6):508-19.